Literature DB >> 3194830

The effect of somatostatin analogue (SMS 201-995) on pancreatic blood flow.

D R Conway1, G Djuricin, R A Prinz.   

Abstract

The effect of somatostatin analogue SMS 201-995 on pancreatic blood flow was studied. In 24 dogs all vessels to the pancreas, except for the pancreaticoduodenal artery and vein, were divided. A flow probe was placed around the pancreaticoduodenal artery. The animals were divided into four groups. Control animals received a subcutaneous injection of 0.5 ml of normal saline solution. Treated animals received 0.002, 0.02, and 0.2 mg/kg of SMS 201-995 at the outset of the experiment. Mean systemic arterial blood pressure, cardiac output, and serum amylase values were monitored, in addition to pancreaticoduodenal blood flow. SMS 201-995 produced a prompt and sustained decrease in pancreatic blood flow in all treated groups compared with control animals without alteration of systemic hemodynamics. This suggests that SMS 201-995 decreases local vascular resistance, which results in decreased pancreatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3194830

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Animal-Use Antibiotics Induce Cross-Resistance in Bacterial Pathogens to Human Therapeutic Antibiotics.

Authors:  Atul K Singh; Arun K Bhunia
Journal:  Curr Microbiol       Date:  2019-07-25       Impact factor: 2.188

2.  Octreotide ameliorates glucose intolerance following acute experimental pancreatitis.

Authors:  B Avni; R Haddad; H Kashtan; D Kaplan; E Graf; A Siegal; Y Skornick; O Kaplan
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

3.  Effects of somatostatin (SMS) on pancreatic microcirculation.

Authors:  T Plusczyk; D Rathgeb; S Westermann; G Feifel
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

4.  Therapeutic applications of octreotide in pediatric patients.

Authors:  Abdulrahman Al-Hussaini; Decker Butzner
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.